Parkinson's disease (PD) is a common neurodegenerative disorder characterized by
degeneration of the substantia nigra pars compacta and by accumulation of α-synuclein in …

Almost 2 decades after linking LRRK2 to Parkinson's disease, a vibrant research field has
developed around the study of this gene and its protein product. Recent studies have begun …

Background Leucine‐rich repeat kinase 2 (LRRK2) inhibition is a promising therapeutic
approach for the treatment of Parkinson's disease (PD). Objective The aim of this study was …

Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

Extracellular vesicles (EVs) are involved in the development and progression of
neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Moreover, EVs …

Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are one of the most frequent
genetic causes of both familial and sporadic Parkinson's disease (PD). Mounting evidence …

Evidence is mounting that LRRK2 function, particularly its kinase activity, is elevated in
multiple forms of Parkinson's disease, both idiopathic as well as familial forms linked to …

Background LRRK2-targeting therapeutics that inhibit LRRK2 kinase activity have advanced
to clinical trials in idiopathic Parkinson's disease (iPD). LRRK2 phosphorylates Rab10 on …

The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held on
27 September to 1 October 2021. Even with a last-minute move from in-person to virtual, an …

Genetic studies have identified variants in the LRRK2 gene as important components of
Parkinson's disease (PD) pathobiology. Biochemical and emergent biomarker studies have …